CR-9114 is under clinical development by Leyden Laboratories and currently in Phase II for Influenza A Virus, H3N2 Subtype Infections. According to GlobalData, Phase II drugs for Influenza A Virus, H3N2 Subtype Infections have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CR-9114’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CR-9114 overview
CR-9114 is under development for the protection against influenza type A Virus (A/Belgium/4217/2015 H3N2 infection, influenza A virus, H5N1 subtype infections and influenza B virus. The drug candidate is a human monoclonal antibody having the broadest activity. It binds to the conserved epitope in the hemagglutinin (HA) stem and protects against the infection. It was also under development for the protection against influenza A (H1N1 and H3N2) and influenza B virus. It is administered through nasal route.
Leyden Laboratories overview
Leyden Laboratories (Leyden Labs) is a biotechnology research company that develops nasal sprays containing antibodies that treats respiratory viruses in the nasal mucosa. The company’s products built through scientific platform supported by harnessing mucosal immunity and broad protection. Leyden Labs nasal sprays deliver antibodies directly to the nasal mucosa to provide the user with immediate anti-viral protection. Its product CR9114, is a human monoclonal antibody that protects against influenza A and B. The company works in collaboration with academics, commercial researchers and other commercial parties. Leyden Labs is headquartered in Leiden, the Netherlands.
For a complete picture of CR-9114’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
